Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry.

Pharmacopsychiatry · 2022 · PMC9259184 · PMID 35045580

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

marginally significantp=0.053so close (0.05 < p ≤ 0.1)

In another phase II DBRCT for 255 female patients with MDD, 30 units of BTA, but not 50 units, showed a marginally significant score reduction in the MADRS compared to placebo at week 6 (primary endpoint, least-squares mean±standard error: −11.6±1.4 versus −7.9±1.4, p=0.053) ( NCT02116361 ) 24 .

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.